Loading...
Market
Story
Medicare to Cover Eli Lilly's Zepbound for Sleep Apnea Following FDA Approval
Jan 8, 2025, 08:34 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent FDA approval, making Zepbound the first medication specifically approved for moderate-to-severe OSA. The coverage under Medicare Part D is expected to enhance the drug's market potential, as it is already recognized as a significant treatment option for obesity-related conditions.
View original story
Similar markets
Yes • 50%
No • 50%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
Novo Nordisk's Wegovy • 25%
Other • 25%
AstraZeneca's Roxadustat • 25%
Pfizer's Danuglipron • 25%
No • 50%
Yes • 50%
More than 80% • 25%
70% to 80% • 25%
60% to 70% • 25%
Less than 60% • 25%
Less than 100,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
100,000 to 200,000 • 25%
3-4 • 25%
5 or more • 25%
0 • 25%
1-2 • 25%
Less than 10% • 25%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%